In a phase 2 clinical trial, the investigational drug selumetinib shrank tumors in some children with the genetic syndrome neurofibromatosis type 1 (NF1). The tumors, called neurofibromas, can cause pain, difficulty breathing or walking, and disfigurement.
https://ift.tt/2MbWH6c
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου